NRG Therapeutics announces senior appointments
Neuroscience company NRG Therapeutics has announced an expansion to its senior team as it advances its neurodegenerative disease treatment NRG5051.
Sarah Almond has been appointed as VP of Translational Biology, David Brocklebank as Director of Clinical Operations, and Kathryn Oliver as Director of Project Management.
Sarah Almond will be responsible for preclinical translational biology and will support the clinical biomarker strategy, David Brocklebank will be responsible for clinical operations supporting delivery of the Phase I and II clinical trials, and Kathryn Oliver will provide project management support for NRG’s clinical asset NRG5051 and preclinical pipeline.
NRG5051 is NRG’s lead candidate for treatment of neurodegenerative diseases, including Parkinson’s. NRG has identified a novel regulator of the mitochondrial permeability transition pore (mPTP), essential for pore opening and amenable to small molecule inhibition. This breakthrough has allowed the company to develop a new class of small molecule mPTP inhibitors, designed to penetrate the brain effectively when taken orally.
The team expansion follows NRG’s recent £50 million ($67 million) Series B financing led by SV Health Investors’ Dementia Discovery Fund (DDF) in a syndicate of leading international life science venture investors including British Business Bank, M Ventures, Novartis Venture Fund and Criteria Bio Ventures.
The new funds provide runway for completion of a Phase II clinical proof of concept study of NRG5051 in amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND), while also generating meaningful clinical data in Parkinson’s patients through a Phase Ib study.
“I am delighted to welcome Sarah, David and Kathryn to the team,” said NRG Therapeutics Co-Founder and CEO Neil Miller.
“Their combined skills and expertise will enable us to efficiently progress NRG5051 through first-in-human clinical trials and into a PoC in ALS/MND, and to lay the ground for development in other indications including Parkinson’s.”
“They join us at a pivotal time as we seek to demonstrate the therapeutic potential of NRG’s first-in-class mPTP inhibitors as disease modifying medicines for neurodegenerative diseases.”
First-in-human studies of NRG5051 are on track to commence in early 2026.
Bruno Quinney, Content Team, DDW
